Mito-Honokiol Compounds Mitochondrial Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using honokiol derivatives face challenges such as significant negative side effects and resistance to chemotherapy and radiotherapy, with limited efficacy at effective doses.
Innovation Solution
Development of mito-honokiol compounds by linking triphenylphosphonium (TPP) to honokiol via long alkyl chains, enhancing lipophilicity and mitochondrial targeting, resulting in compounds that are 100-1000 fold more potent at nanomolar concentrations with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If honokiol is used to treat cancer, then antitumor effects are achieved, but significant negative side effects occur and resistance develops
Solution Approach 1:
The patent applies local quality by modifying honokiol to create mito-honokiol with distinct functional regions: the honokiol core maintains antitumor activity while the TPP cation with long alkyl chain provides selective mitochondrial targeting. This localized modification concentrates the therapeutic effect in tumor mitochondria while protecting healthy cells, thereby maintaining efficacy and reducing side effects simultaneously
Solution Approach 2:
The TPP cation acts as an intermediary that mediates the delivery of honokiol to tumor mitochondria. The TPP moiety exploits the enhanced negative membrane potential of tumor mitochondria to facilitate accumulation, serving as a bridge between systemic administration and selective intracellular targeting, thus improving therapeutic index
2Reliability
If modified honokiol is used to inhibit angiogenesis, then efficacy is enhanced, but significant negative side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the lipophilicity and mitochondrial targeting parameters of honokiol through TPP conjugation with long alkyl chains (C10-C18). These parameter changes enable selective accumulation in tumor mitochondria at nanomolar concentrations, enhancing efficacy while the selective targeting reduces off-target side effects compared to previous angiogenesis inhibitors
3Reliability
If higher doses of honokiol are used to overcome resistance, then efficacy increases, but side effects increase
Solution Approach 1:
The mito-honokiol compound applies self-service by exploiting the inherent enhanced negative membrane potential of tumor mitochondria to drive its own selective accumulation. This self-targeting mechanism ensures high concentrations are achieved in tumor cells at low systemic doses, overcoming resistance without proportionally increasing toxicity to healthy cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mito-honokiol compounds effectively inhibit cancer cell proliferation and metastasis, synergizing with antiglycolytic agents, and overcoming chemotherapy resistance, while showing minimal toxicity to healthy cells, thus offering a potent and targeted anti-cancer therapy.
Implementation Method 1
TPP cations possess lipophilic character and therefore cross cellular membranes and accumulate into mitochondria due to the enhanced negative membrane potential of tumor mitochondria
Implementation Method 2
The long alkyl chain linking honokiol to TPP moieties has two advantages: (a) it increases the lipophilic character of the compound, leading to an enhanced cellular uptake
Data Source
AI summary
The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.